PulseAugur
EN
LIVE 03:38:15

Akeso's lung cancer drug shows 34% reduced death risk in trials

By PulseAugur Editorial · [1 sources] ·

Akeso's lung cancer drug, ivonescimab, has shown significant promise in phase three clinical trials, reducing the risk of death by 34%. The drug demonstrated a notable survival benefit, with 64.7% of patients alive after two years compared to 48.6% in the control group. Analysts are optimistic about its potential to transform non-small cell lung cancer therapy and capture a substantial share of the global market, though the company's stock saw a slight dip. AI

RANK_REASON Clinical trial results for a drug are presented. [lever_c_demoted from research: ic=1 ai=0.0]

Read on SCMP — Tech →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Akeso's lung cancer drug shows 34% reduced death risk in trials

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
Clinical trial results for a drug are presented. [lever_c_demoted from research: ic=1 ai=0.0]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
86 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. SCMP — Tech TIER_1 English(EN) · Julie Zhang ·

    Akeso lung cancer drug shines in trials, boosting hopes in US$20b market

    Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses. Analysts suggest i…

RELATED ENTITIES

RELATED TOPICS